
FAQ: Can You Recapture Response to IL-17i Therapy After Interruption or Discontinuation in Therapy?
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Acerca de esta escucha
Join Audrey Gibson, PA-C, a seasoned rheumatology provider at the Arthritis Center of North Georgia with 18 years of clinical experience, as she explores the question: Can patients recapture their response to IL-17 inhibitor therapy after an interruption or discontinuation?
In this discussion, Audrey reviews key findings from a pivotal clinical trial by Landewé et al., which examined the recapture and retreatment rates of Ixekizumab in axial spondyloarthritis (axSpA) after therapy withdrawal. The randomized, placebo-controlled study followed 155 patients with axSpA who achieved remission and were either continued on Ixekizumab or switched to placebo.
Key results from the study revealed that 96% of patients who withdrew to placebo were able to recapture low disease activity upon retreatment, while 71% regained inactive disease status. These findings offer critical insights for rheumatology providers counseling patients who experience therapy interruptions due to illness, infection, surgery, or personal choice.
This discussion provides a valuable clinical perspective on IL-17 inhibitor retreatment strategies and helps answer common patient concerns about treatment withdrawal and re-initiation.
For more expert insights on IL-17 inhibition and axial spondyloarthritis management, visit RhAPP.org or explore additional educational content on the RhAPP ACE App.